Novartis AG's purchase of a priority review vouchers from rare disease developer Ultragenyx Pharmaceutical Inc. may indicate a strategy to build a stockpile of the coupons in order to race to market against potential competition.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?